{"url_path":"/sec/mist/8-k/2026-05-13/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1408443/0001104659-26-059780-index.html","accession_number":"0001104659-26-059780","cik":"0001408443","ticker":"MIST","issuer_name":"Milestone Pharmaceuticals Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1408443/0001104659-26-059780-index.html","primary_entity_key":"0001408443","primary_entity_name":"Milestone Pharmaceuticals Inc."},"word_count":319,"has_tables":true,"body_markdown":"false\n0001408443\nA8\n00-0000000\nQC\n\n0001408443\n\n2026-05-13\n2026-05-13\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of the\nSecurities Exchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event reported):\n\n**May 13, 2026**\n\n \n\n**MILESTONE\nPHARMACEUTICALS INC.**\n\n(Exact name of registrant as specified in its\ncharter)\n\n \n\nQuébec\n \n001-38899\n \nNot\napplicable\n\n(state or other jurisdiction of incorporation)\n \n(Commission File Number)\n \n(I.R.S. Employer Identification No.)\n\n \n\n1111\nDr. Frederik-Philips Boulevard,\n \n \n\nSuite\n420\n \n \n\nMontréal,\nQuébec CA\n \nH4M\n2X6\n\n(Address of principal executive offices)\n \n(Zip Code)\n\n \n\nRegistrant's telephone number, including area\ncode: **(514****)\n336-0444**\n\n \n\n(Former\nname or former address, if changed since last report.)\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General\nInstruction A.2. below):\n\n \n\n¨Written\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨Soliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b)\nof the Act:\n\n \n\nTitle of each class\n \nTrading Symbol(s)\n \nName of each exchange on which\n\nregistered\n\nCommon\nShares\n \nMIST\n \nThe\nNasdaq Stock Market LLC\n\n \n\nIndicate by check mark\nwhether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405\nof this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).\n\n \n\nEmerging growth company\n¨\n\n \n\nIf an emerging growth\ncompany, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or\nrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}